Non-phosphorylated tau as a potential biomarker of Alzheimer's Disease: Analytical and diagnostic characterization

Journal of Alzheimer's Disease

Volumn 55, Issue 1, 2017, Pages 159-170

  Lewczuk, Piotr ^a,k   Lelental, Natalia ^a   Lachmann, Ingolf ^b   Holzer, Max ^c   Flach, Katharina ^b   Brandner, Sebastian ^d   Engelborghs, Sebastiaan ^e,f   Teunissen, Charlotte E ^g   Zetterberg, Henrik ^h,i   Molinuevo, José Luis ^j   Mroczko, Barbara ^k   Blennow, Kaj ^h   Popp, Julius ^l   Parnetti, Lucilla ^m   Chiasserini, Davide ^m   Perret Liaudet, Armand ^n,o   Spitzer, Philipp ^a   Maler, Juan Manuel ^a   Kornhuber, Johannes ^a  

^a Lab for Clinical Neurochemistry and Neurochemical Dementia Diagnostics   (Germany)

^b Roboscreen GmbH Leipzig   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^e UNIVERSITY OF ANTWERP   (Belgium)

^f Hospital Network Antwerp ZNA Middelheim and Hoge Beuken   (Belgium)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF GOTHENBURG   (Sweden)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^j HOSPITAL CLÍNIC   (Spain)

^k MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^l LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^m UNIVERSITY OF PERUGIA   (Italy)

ⁿ HOSPICES CIVILS DE LYON   (France)

^o LYON NEUROSCIENCE RESEARCH CENTER   (France)

more..

Author keywords

Biomarkers; cerebrospinal fluid; phosphorylation; tau

Indexed keywords

BIOLOGICAL MARKER; EPITOPE; IMMUNOGLOBULIN ANTIBODY; TAU PROTEIN; IMMUNOGLOBULIN G; MAPT PROTEIN, HUMAN;

AGED; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; DEMENTIA; HUMAN; MILD COGNITIVE IMPAIRMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SENSITIVITY AND SPECIFICITY; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; CEREBROSPINAL FLUID; COGNITIVE DEFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FEMALE; GENETICS; MALE; PHOSPHORYLATION; PROCEDURES; PROTEIN STABILITY; REPRODUCIBILITY; SPECIMEN HANDLING; TEMPERATURE;

AGED; ALZHEIMER DISEASE; ANIMALS; BIOMARKERS; CELLS, CULTURED; COGNITIVE DYSFUNCTION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MICE, INBRED BALB C; PHOSPHORYLATION; PROTEIN STABILITY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECIMEN HANDLING; TAU PROTEINS; TEMPERATURE;

EID: 84994577084     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-160448     Document Type: Article

References (34)

1. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer?s disease: Recommendations from the National Institute on Aging-Alzheimer?s Association workgroups on diagnostic guidelines for Alzheimer?s disease. Alzheimers Dement 7, 263-269.
2. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH (2011) The diagnosis of mild cognitive impairment due to Alzheimer?s disease: Recommendations from the National Institute on Aging-Alzheimer?s Association workgroups on diagnostic guidelines for Alzheimer?s disease. Alzheimers Dement 7, 270-279.
3. (2009) S3-Leitlinie "Demenzen". http://www.dggpp.de/documents/s3-leitlinie-demenz-kf.pdf.
4. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert MO, Jicha GA, Nordberg A, Pasquier F, Rabinovici G, Robert P, Rowe C, Salloway S, Sarazin M, Epelbaum S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL (2014) Advancing research diagnostic criteria for Alzheimer?s disease: The IWG-2 criteria. Lancet Neurol 13, 614-629.
5. Lleo A, Cavedo E, Parnetti L, Vanderstichele H, Herukka SK, Andreasen N, Ghidoni R, Lewczuk P, Jeromin A, Winblad B, Tsolaki M, Mroczko B, Visser PJ, Santana I, Svenningsson P, Blennow K, Aarsland D, Molinuevo JL, Zetterberg H, Mollenhauer B (2015) Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nat Rev Neurol 11, 41-55.
6. European Medicines Agency (2012) Qualification opinion of Alzheimer?s disease novel methodologies/biomarkers for the use of CSFA-1-42 and t-Tau and/or PET-Amyloid imaging (EMA/CHMP/SAWP/893622/2011).
7. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer?s pathological cascade. Lancet Neurol 9, 119-128.
8. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer?s disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol 5, 228-234.
9. Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6, 131-144.
10. Lewczuk P, Kornhuber J (2011) Neurochemical dementia diagnostics in Alzheimer?s disease: Where are we now and where are we going? Expert Rev Proteomics 8, 447-458.
11. Barage SH, Sonawane KD (2015) Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer?s disease. Neuropeptides 52, 1-18.
12. Morris GP, Clark IA, Vissel B (2014) Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer?s disease. Acta Neuropathol Commun 2, 135.
13. Pedersen JT, Sigurdsson EM (2015) Tau immunotherapy for Alzheimer?s disease. Trends Mol Med 21, 394-402.
14. Braak H, Braak E (1996) Evolution of the neuropathology of Alzheimer?s disease. Acta Neurol Scand Suppl 165, 3-12.
15. Holzer M, Holzapfel HP, Zedlick D, Bruckner MK, Arendt T (1994) Abnormally phosphorylated tau protein in Alzheimer?s disease: Heterogeneity of individual regional distribution and relationship to clinical severity. Neuroscience 63, 499-516.
16. Flach K, Hilbrich I, Schiffmann A, Gartner U, Kruger M, Leonhardt M, Waschipky H, Wick L, Arendt T, Holzer M (2012) Tau oligomers impair artificial membrane integrity and cellular viability. J Biol Chem 287, 43223-43233.
17. Lewczuk P, Kornhuber J, Wiltfang J (2006) The German Competence Net Dementias: Standard operating procedures for the neurochemical dementia diagnostics. J Neural Transm 113, 1075-1080.
18. Wang JZ, Liu F (2008) Microtubule-Associated protein tau in development, degeneration and protection of neurons. Prog Neurobiol 85, 148-175.
19. Martin L, Latypova X, Wilson CM, Magnaudeix A, Perrin ML, Yardin C, Terro F (2013) Tau protein kinases: Involvement in Alzheimer?s disease. Ageing Res Rev 12, 289-309.
20. Hanger DP, Anderton BH, Noble W (2009) Tau phosphorylation: The therapeutic challenge for neurodegenerative disease. Trends Mol Med 15, 112-119.
21. Bancher C, Brunner C, Lassmann H, Budka H, Jellinger K, Wiche G, Seitelberger F, Grundke-Iqbal I, Iqbal K, Wisniewski HM (1989) Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer?s disease. Brain Res 477, 90-99.
22. Morris M, Knudsen GM, Maeda S, Trinidad JC, Ioanoviciu A, Burlingame AL, Mucke L (2015) Tau post-Translational modifications in wild-Type and human amyloid precursor protein transgenic mice. Nat Neurosci 18, 1183-1189.
23. Lewczuk P, Esselmann H, Bibl M, Beck G, Maler JM, Otto M, Kornhuber J, Wiltfang J (2004) Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer?s disease: Original data and review of the literature. J Mol Neurosci 23, 115-122.
24. Blennow K, Dubois B, Fagan AM, Lewczuk P, de Leon MJ, Hampel H (2015) Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer?s disease. Alzheimers Dement 11, 58-69.
25. Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, Sjoegren M, DeBernardis J, Kerkman D, Ishiguro K, Ohno H, Vanmechelen E, Vanderstichele H, McCulloch C, Moller HJ, Davies P, Blennow K (2004) Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: A comparative cerebrospinal fluid study. Arch Gen Psychiatry 61, 95-102.
26. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ (2009) Cerebrospinal fluid biomarker signature in Alzheimer?s disease neuroimaging initiative subjects. Ann Neurol 65, 403-413.
27. Behrouzi R, Liu X, Wu D, Robinson AC, Tanaguchi-Watanabe S, Rollinson S, Shi J, Tian J, Hamdalla HH, Ealing J, Richardson A, Jones M, Pickering-Brown S, Davidson YS, Strong MJ, Hasegawa M, Snowden JS, Mann DM (2016) Pathological tau deposition in Motor Neurone Disease and frontotemporal lobar degeneration associated with TDP-43 proteinopathy. Acta Neuropathol Commun 4, 33.
28. Meredith JE Jr, Sankaranarayanan S, Guss V, Lanzetti AJ, Berisha F, Neely RJ, Slemmon JR, Portelius E, Zetterberg H, Blennow K, Soares H, Ahlijanian M, Albright CF (2013) Characterization of novel CSF Tau and ptau biomarkers for Alzheimer?s disease. PLoS One 8, e76523.
29. Mandelkow EM, Mandelkow E (2012) Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med 2, a006247.
30. Lewczuk P, Lelental N, Spitzer P, Maler JM, Kornhuber J (2015) Amyloid-42/40 CSF concentration ratio in the diagnostics of Alzheimer?s Disease: Validation of two novel assays. J Alzheimers Dis 43, 183-191.
31. Lewczuk P, Beck G, Ganslandt O, Esselmann H, Deisenhammer F, Regeniter A, Petereit HF, Tumani H, Gerritzen A, Oschmann P, Schröder J, Schonknecht P, Zimmermann K, Hampel H, Bürger K, Otto M, Haustein S, Herzog K, Dannenberg R, Würster U, Bibl M, Maler JM, Reubach U, Kornhuber J, Wiltfang J (2006) International quality control survey of neurochemical dementia diagnostics. Neurosci Lett 409, 1-4.
32. Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, Fagan AM, Forlenza O, Frisoni GB, Galasko D, Galimberti D, Hampel H, Handberg A, Heneka MT, Herskovits AZ, Herukka SK, Holtzman DM, Humpel C, Hyman BT, Iqbal K, Jucker M, Kaeser SA, Kaiser E, Kapaki E, Kidd D, Klivenyi P, Knudsen CS, Kummer MP, Lui J, Llado A, Lewczuk P, Li QX, Martins R, Masters C, McAuliffe J, Mercken M, Moghekar A, Molinuevo JL, Montine TJ, Nowatzke W, O?Brien R, Otto M, Paraskevas GP, Parnetti L, Petersen RC, Prvulovic D, de Reus HP, Rissman RA, Scarpini E, Stefani A, Soininen H, Schröder J, Shaw LM, Skinningsrud A, Skrogstad B, Spreer A, Talib L, Teunissen C, Trojanowski JQ, Tumani H, Umek RM, Van Broeck B, Vanderstichele H, Vecsei L, Verbeek MM, Windisch M, Zhang J, Zetterberg H, Blennow K (2011) The Alzheimer?s Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 7, 386-395 e386.
33. Lewczuk P, Zimmermann R, Wiltfang J, Kornhuber J (2009) Neurochemical dementia diagnostics: A simple algorithm for interpretation of the CSF biomarkers. J Neural Transm 116, 1163-1167.
34. Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M, Holtta M, Rosen C, Olsson C, Strobel G, Wu E, Dakin K, Petzold M, Blennow K, Zetterberg H (2016) CSF and blood biomarkers for the diagnosis of Alzheimer?s disease: Asystematic reviewand meta-Analysis. Lancet Neurol 15, 673-684.